 |
|
|
 |
Case Report
Treatment of Orbital Myositis with Adalimumab (Humira)
ALEXA B. ADAMS, MICHAEL KAZIM, and THOMAS J.A. LEHMAN ABSTRACT. Adalimumab is a fully humanized IgG1 monoclonal antibody to tumor necrosis factor-a. We describe 2 patients (17 and 13 years of age) with refractory, steroid-dependent, recurrent nonspecific orbital myositis not controlled with standard immunosuppressive medications. Both improved with adalimumab treatment, allowing reduction in corticosteroid dosage without disease flare. (J Rheumatol 2005;32:1374-5) Key Indexing Terms: ADALIMUMAB From the Division of Pediatric Rheumatology, Hospital for Special Surgery; and Department of Ophthalmology, New York Presbyterian Hospital, Columbia Campus, New York, New York, USA. A.B. Adams, MD, Fellow, Division of Pediatric Rheumatology, Hospital for Special Surgery; T.J.A. Lehman, MD, Chief, Division of Pediatric Rheumatology, Hospital for Special Surgery, Professor of Clinical Pediatrics, Weill Cornell Medical Center, New York, NY; M. Kazim, MD, Department of Ophthalmology, New York Presbyterian Hospital. Address reprint requests to Dr. T.J.A. Lehman, Division of Pediatric Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021. Accepted for publication February 3, 2005. |